New class of agents in the treatment of prostate cancer.
March 2nd, 2010 Posted in prostate cancerA scientific team proposes the potential of a whole new class of agents in the treatment of prostate cancer.
Researchers have reported data suggesting that some selective estrogen receptor-? (ER?) agonists may have efficacy in the treatment of prostate cancer - most specifically in patients who are refractory to standard forms of hormone therapy. Their study is based on the effects of the selective ER? agonist known as 8?-VE2 in mice, so it will be a while before we know whether this strategy actually works in man.
It may be possible to used ER? agonists and other forms of estrogen therapy in the treatment of prostate cancer and BPH, but there will be a lot of work to do before we can be certain.
In the same paper published in the Proceedings of the National Academy of Science, the authors also report data suggesting that ER? agonists might be useful in the management of benign prostatic hyperplasia or enlargement of the prostate.